NCT04218162View on ClinicalTrials.gov

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

PHASE3CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

October 30, 2020

Study Completion Date

October 30, 2020

Conditions
Acute Migraine
Interventions
DRUG

Lasmiditan 50mg

Lasmiditan 50mg

DRUG

Lasmiditan 100mg

Lasmiditan 100mg

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

IlDong Pharmaceutical Co Ltd, Seoul

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT04218162 - Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean | Biotech Hunter | Biotech Hunter